VAQTA Vaccine for Hepatitis A: Schedule, Safety, and Havrix

VAQTA is an inactivated hepatitis A vaccine manufactured by Merck, and it is one of two hepatitis A vaccines available in the United States (the other being Havrix, made by GlaxoSmithKline). It works by exposing your immune system to a killed version of the hepatitis A virus, prompting it to build antibodies without causing infection. The vaccine has been in use since the mid-1990s and was central to the first clinical trial that proved hepatitis A vaccination could prevent the disease in a real-world community setting.

What VAQTA Protects Against

Hepatitis A is a liver infection caused by the hepatitis A virus, which spreads mainly through contaminated food or water or close contact with an infected person. Unlike hepatitis B and C, hepatitis A doesn’t become a chronic infection, but it can make you seriously ill for weeks or months, causing fatigue, nausea, abdominal pain, jaundice, and occasionally liver failure. In rare cases, especially among older adults or people with preexisting liver disease, it can be fatal. VAQTA is designed to prevent all of this by training the immune system to recognize the virus before you ever encounter it.

The vaccine is approved for anyone aged 12 months and older. Current U.S. guidelines recommend routine hepatitis A vaccination for all children starting at age one, along with vaccination for adults who are at increased risk, including travelers to countries where hepatitis A is common, people with chronic liver disease, people experiencing homelessness, men who have sex with men, and people who use injection or non-injection drugs. In 2020, the Advisory Committee on Immunization Practices broadened the recommendation to include all adults who want protection, regardless of specific risk factors.

Dosing Schedule

VAQTA is given as a two-dose series. The first shot is followed by a booster six to eighteen months later. Children aged 12 months through 18 years receive 25 units per dose, while adults get 50 units per dose. Both doses are injected into the muscle, typically the upper arm for adults and older children, or the thigh for toddlers.

The timing of the booster matters for building the strongest long-term protection, but even a single dose provides substantial short-term immunity. In the original field trial conducted in the Kiryas Joel community in Monroe, New York, a single dose proved highly effective at stopping hepatitis A transmission during an outbreak.¹ The second dose, however, is what drives antibody levels high enough to last for decades.

How Well It Works

VAQTA generates a strong immune response quickly. In a study of young adults, every participant who received VAQTA had developed protective antibodies by four weeks after the first dose, and antibody levels continued climbing through the six-month mark before the booster.² After the booster, antibody concentrations jumped dramatically, reaching levels well above what’s considered protective.

The speed of the initial immune response does vary somewhat from person to person. In a crossover trial involving 201 volunteers, about 43% of those who received VAQTA first had seroconverted by two weeks, rising to 93% by four weeks and 100% by 26 weeks.³ That early ramp-up period is worth knowing about if you’re getting vaccinated shortly before traveling to a high-risk area: you’re not fully protected after just a few days, though partial protection builds rapidly over the first month.

VAQTA Versus Havrix

Since both VAQTA and Havrix are inactivated hepatitis A vaccines, people naturally wonder whether one is better than the other. The short answer is that both work well and produce similar protection, but the details reveal some interesting differences in how the immune system responds to each.

In the crossover trial mentioned above, VAQTA consistently produced higher antibody concentrations than Havrix at every time point measured. At four weeks after the first dose, the geometric mean antibody concentration was about 189 mIU/mL for VAQTA versus 114 mIU/mL for Havrix. At six months, the gap widened further. After the full two-dose series, those who received two doses of VAQTA had roughly double the antibody levels of those who received two doses of Havrix.⁴ However, seroconversion rates were similar between the two vaccines, meaning virtually everyone developed protective antibody levels regardless of which vaccine they received.

A separate study in young adults confirmed this pattern, finding that both vaccines reached 100% seroconversion by six months and that antibody titers after the booster were statistically similar between the two.⁵ The researchers themselves characterized both vaccines as having “similar immunogenicity.” Whether higher raw antibody numbers translate into meaningfully longer protection is still an open question, one that the crossover trial authors acknowledged when they noted that “the significance of higher anti-HAV antibody concentrations in terms of long-term protection is unknown.”⁶

For practical purposes, you should get whichever vaccine is available. Both are highly effective, and the clinical differences between them are unlikely to matter for real-world protection.

Can You Mix and Match Doses?

Yes. If you got your first hepatitis A shot with one brand and only have access to a different brand for the booster, you’re fine. Clinical trials have specifically tested this. In the crossover study, volunteers who received VAQTA followed by Havrix, or Havrix followed by VAQTA, achieved high antibody levels after the second dose. An interesting wrinkle: when VAQTA was used as the booster (regardless of which vaccine came first), the resulting antibody levels were higher than when Havrix was the booster.⁷

A pediatric study in Turkey looked at interchangeability with a third hepatitis A vaccine (Avaxim), giving children a second dose of Avaxim after a first dose of either VAQTA or Havrix. All children were seroprotected before and after the second dose, with no significant differences in antibody levels between those who received two doses of the same vaccine and those who switched brands.⁸ The practical takeaway: don’t delay getting your second dose just because the exact same brand isn’t available.

How Long Does Protection Last?

This is one of the more reassuring aspects of VAQTA. Protection appears to last for decades. Mathematical modeling based on observed antibody decline in children and adolescents who received the full two-dose series suggests that over 99% of vaccinated people will still have detectable hepatitis A antibodies 25 to 50 years after vaccination.⁹ That’s a projection, not a direct observation (the vaccine hasn’t been around for 50 years yet), but the trajectory of antibody persistence in follow-up studies has been consistently encouraging.

Beyond circulating antibodies, there’s also immunological memory to consider. Even if measurable antibody levels eventually fall below the detection threshold, the immune system retains memory cells that can mount a rapid response if the virus shows up. Early analysis of VAQTA’s durability concluded that protection would extend through both persistent antibody and this backup memory response.¹⁰ Based on existing evidence, no booster beyond the initial two-dose series is currently recommended for people with healthy immune systems.

Safety and Side Effects

VAQTA’s safety profile has been studied extensively. A large trial involving over 4,300 children aged 12 to 23 months found that the most common reaction was pain or tenderness at the injection site, reported by about a quarter of recipients after each dose. Redness at the injection site affected roughly 14-15% of children. Among systemic reactions, fever (at or above 100.4°F) occurred in about 12% and irritability in about 8%.¹¹ These are typical vaccine side effects that resolve on their own within a day or two.

Serious adverse events were rare. In that same trial, 0.4% of participants experienced a serious adverse event of any kind, but only 0.1% were considered related to the vaccine. No deaths occurred within 14 days of receiving a dose.¹² The overall safety picture was similar whether VAQTA was given alone or at the same visit as other childhood vaccines. As with any vaccine, severe allergic reactions are possible but extremely rare, and the vaccine should not be given to anyone with a known allergy to any of its components.

Getting VAQTA Alongside Other Vaccines

One practical concern for parents and clinicians is whether VAQTA can be given at the same appointment as other routine childhood shots. For the most part, yes. A study of healthy 12-month-old children evaluated VAQTA given alongside standard vaccines for measles, mumps, rubella, varicella, diphtheria, tetanus, pertussis, and polio. The safety profile was generally comparable whether VAQTA was given alone or together with those other shots.¹³

When given alone, VAQTA produced a seropositivity rate of 98.3% after the first dose and 100% after the second. Most of the other vaccines maintained their expected immune responses when co-administered. However, the study did note that immune responses to varicella and one component of the pertussis vaccine were somewhat lower than historical benchmarks when given at the same time as VAQTA.¹⁴ This didn’t necessarily mean reduced real-world protection, but it’s worth noting as part of the clinical picture. Current guidelines still support co-administration, and your child’s pediatrician will follow the recommended scheduling that accounts for these interactions.

Using VAQTA After an Exposure

If you’ve been exposed to someone with hepatitis A, getting vaccinated quickly can still help. VAQTA and other hepatitis A vaccines have been studied as post-exposure prophylaxis, which means using them after a known contact rather than purely as a preventive measure ahead of time. Traditionally, immune globulin (a concentrated dose of antibodies from donated blood) was the go-to treatment after exposure. A landmark trial compared the two approaches head-to-head and found that the vaccine provided good protection, meeting the study’s criterion for being noninferior to immune globulin.¹⁵

Hepatitis A rates were low in both groups, though the vaccine group did have slightly higher rates of infection, suggesting a small possible edge for immune globulin in the very short term. The researchers noted this might be “clinically meaningful in some settings,” particularly among people at higher risk for severe disease. Vaccine has a clear advantage in other respects, though: it provides lasting protection through immune memory, while immune globulin offers only temporary passive protection that fades within a few months.¹⁶ Current U.S. guidelines generally recommend the vaccine for healthy people aged 12 months through 40 years who’ve been exposed, while immune globulin is preferred for infants under 12 months, immunocompromised individuals, and people with chronic liver disease where the stakes of even a modest efficacy gap are higher.

The Bigger Public Health Story

VAQTA played a significant role in the dramatic decline of hepatitis A in the United States and other countries that adopted universal childhood vaccination programs. Before routine vaccination began, hepatitis A was one of the most commonly reported vaccine-preventable diseases in the U.S., with tens of thousands of cases reported annually and many more going unreported. After universal vaccination of children was recommended in 2006, cases plummeted.

Systematic reviews of countries that introduced universal hepatitis A vaccination programs found rapid and sustained declines in hepatitis A across all age groups, including in people who weren’t vaccinated themselves.¹⁷ That indirect protection is a hallmark of herd immunity: when enough children are vaccinated, the virus has fewer hosts to circulate through, which protects unvaccinated adults and infants too. A separate systematic review confirmed this pattern, showing marked declines in hepatitis A incidence in both vaccinated and unvaccinated age groups after universal mass vaccination was introduced in countries with moderate rates of infection.¹⁸

There is a paradox embedded in that success, though. As hepatitis A becomes rarer, fewer people develop natural immunity from exposure, which leaves growing pools of susceptible adults. That dynamic has contributed to sporadic outbreaks in recent years, particularly among people experiencing homelessness and people who use drugs, groups with lower vaccination rates and conditions that facilitate person-to-person transmission. The outbreaks are a reminder that individual vaccination remains important even when overall disease rates are low.

People With Chronic Liver Disease

Hepatitis A vaccination takes on special urgency for people who already have chronic liver disease, whether from hepatitis B, hepatitis C, alcohol use, or fatty liver disease. While hepatitis A doesn’t cause chronic liver damage on its own, it can trigger acute liver failure when layered on top of an already compromised liver. The risk of a severe or fatal outcome from hepatitis A is substantially higher in people with underlying liver conditions, which is why vaccination is strongly recommended for this group.

The challenge is that people with advanced liver disease or those who are immunocompromised (including liver transplant recipients on anti-rejection medications) tend to mount weaker immune responses to vaccines in general. Antibody levels after hepatitis A vaccination may be lower, and protection may not last as long. For transplant candidates, the ideal time to vaccinate is before the transplant, while the immune system is still functioning more normally. If vaccination hasn’t happened by the time someone is post-transplant and on immunosuppressive therapy, the vaccine can still be given, but the response is less predictable and antibody levels should be checked afterward to confirm protection.

One-Dose Versus Two-Dose Programs

An ongoing debate in global public health is whether a single dose of hepatitis A vaccine might be sufficient for population-level control, particularly in middle-income countries where cost and logistics are barriers to completing a two-dose series. Several countries, including Argentina and Brazil, have implemented single-dose programs with encouraging results. A systematic review found that single-dose programs produced rapid declines in hepatitis A incidence that persisted for at least six years, the longest follow-up available at the time.¹⁹ Two-dose programs showed sustained declines for at least 14 years.

The question isn’t whether one dose works in the short term. It clearly does. The uncertainty is about how long single-dose protection holds up on an individual level and what happens as herd immunity effects interact with declining individual antibody levels over many years. The modeling data for VAQTA specifically tracks the two-dose series, projecting detectable antibodies in over 99% of recipients at the 25-to-50-year mark.²⁰ Whether a single dose can match that kind of longevity remains one of the bigger unanswered questions in hepatitis A prevention. For now, the U.S. recommendation remains a two-dose series, and if you’ve only gotten one dose, it’s worth completing the series regardless of how much time has passed since the first shot. The booster can be given at any point without needing to restart.